Evidence-domain translation in the Lyme disease controversy over persistent post-treatment symptoms
The findings show a recurring distinction between mechanism-level evidence and the evidence needed to establish patient-level causation or durable clinical benefit, and map how different forms of evidence are distributed and translated across the PTLDS–CLD literature.
Teo Sušnjak, Lorenz Brehme, Kunal Garg et al.
· Frontiers in Cellular and In... · 0 citations